Herein, we demonstrate that the downregulation of SETD2 facilitates imatinib resistance in CML cells, with LSC marker upregulation, which could be successfully rescued by SETD2 overexpression. Here, SETD2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.